To NASDAQ OMX Copenhagen A/S
Announcement no. 21-12 / Copenhagen, November 12, 2012
Today, Topotarget announced that the Board of Directors has reviewed and approved the company’s interim report for the period January 1 to September 30, 2012.
Highlights from the financial results for the period January 1 to September 30, 2012:
A teleconference will be held today at 2:00 pm CET.
CEO Anders Vadsholt will present the interim report for Q3 2012 and answer questions. The teleconference will be conducted in English. A presentation will be available on Topotarget’s website, www.topotarget.com, before the start of the conference call.
To participate in the conference call please dial:
You will be able to stream the telephone conference via the following link: http://storm.zoomvisionmamato.com/player/topotarget/objects/wcd3h1v6/
After the call, a playback will be available via the same link.
For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345; Cell: +45 28989055
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.